Skip to main content
Premium Trial:

Request an Annual Quote

Number Crunch Pipe Dreams?

Premium

Pipe Dreams?

Pharmas like to dismiss genomics-cum-drug companies, saying that developing a viable pipeline requires a lot more than an altered business plan. But genomics execs argue that once their products get to market, they’ll get the recognition they deserve. GT checked out the pipelines of a sampling of companies that rely on genomics, or were genomics shops in former lives.

Oxford GlycoSciences

Genomics- and proteomics-based discovery has led to:

6 products in lead discovery

2 products in pre-clinical development

1 product in clinical development

1 product in regulatory review

 

Millennium Pharmaceuticals

Shifted from pure genomic focus to drugs early on:

8 products in Phase I

1 product in Phase II

1 product as far as Phase III

 

Human Genome Sciences

Vaunts traditional discovery with genomics spin:

4 products in pre-clinical

4 products in Phase I

1 product in Phase II

 

Vertex Pharmaceuticals

With an arsenal relying on chemogenomics, this company has:

2 products in research stage

8 products in pre-clinical

2 products in Phase I

5 products in Phase II

1 product in Phase III

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.